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practice in central Massachusetts were used to identify 1777 patients age q65 years 
as of January 1, 2006 with continuous medical and pharmacy coverage in 2005 
(baseline) and 2006 (study period) and q1 depression diagnosis in 2005. Patients with 
q1 antidepressant claim in 2006 were classiﬁ ed as “treated” and those without an 
antidepressant as “untreated.” Depressed patients were randomly matched to controls 
without depression on age and gender. Baseline comorbidity proﬁ les were compared 
using Chi-square tests. Wilcoxon rank-sum tests and generalized linear models were
used to compare study period direct (medical and pharmacy) costs deﬁ ned as third 
party payments to providers. Depression-related costs were identiﬁ ed using claims
with depression diagnosis and antidepressant prescriptions. RESULTS: A total of 1334 
(75.1%) of depressed patients were treated with antidepressants during the study
period and 443 patients (24.9%) were not treated. Depressed patients were on average 
77 years old and 74.8% were women. Depressed patients had higher rates of mental 
health and physical comorbidities than controls. Treated depressed patients had higher 
rates of mental health comorbidities than the untreated but few differences in rates of 
physical comorbidities. During the study period average annual direct costs were
$14,362 among treated depressed patients, $8,928 among the untreated, and $6,961 
among controls (P  0.01 for all comparisons). Risk-adjusted direct costs were
signiﬁ cantly different between the treated and untreated depressed. Average depres-
sion-related costs were $1,582 among the treated and $133 among the untreated (P
 0.01). CONCLUSIONS: Older depressed patients (both treated and untreated) had
more comorbidities and higher costs compared to controls. Costs and rates of mental
health comorbidities were higher among the treated depressed compared with the
untreated.
PMH30
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OBJECTIVES: To estimate hospitalization costs as well as resources used by schizo-
phrenic patients during a relapse in a public psychiatric hospital. METHODS: A 
documental retrospective analysis of schizophrenia patients with a relapse as the 
principal diagnosis was carried out in a public psychiatric hospital in Mexico. The
range of patients’ age was from 18 to 64 years. Data was collected by a General Physi-
cian through a Case Report Form designed speciﬁ cally for this study. Resources used 
during relapse hospitalization were accrued and ﬁ nal costs were calculated using
unitary costs of the Mexican Social Security Institute (IMSS) for laboratory studies,
physician’s visit, emergency admittance and bed day. Drug costs were obtained from 
public bids of the same institution. Results are presented using descriptive statistics. 
Costs are in US dollars using and exchange rate of 13.5 MXN pesos for 1 US dollar. 
RESULTS: Sample size was of 73 patients with an average follow up of 3.3 years. 
Hospital average length of stay was 20.65 days (4–108), average time between relapses
was 14.66 months (6.47–25.73). The average cost per day was $346 (95% IC,
$331–$360), 96% of this cost represents the average bed day cost reported by the
IMSS. The average cost per relapse was $7,086 ($1,498–$36,288). Alcoholism and 
hypertension were the main comorbidities reported in 10.8% of admitted patients. 
Lack of compliance was the reason for relapse in 95% of the cases. CONCLUSIONS:
Bed day cost is the main component of total costs, therefore it would make sense to 
use those antipsychotic drugs that help reduce the hospital length of stay. The lack of 
compliance is responsible for the vast majority of relapses (95%). A health care 
program focus in increasing drug compliance could decrease institutional general costs
by reducing hospitalizations due to relapses.
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OBJECTIVES: Efﬁ cacy in bipolar disorder (BPD) has been demonstrated for various
atypical antipsychotics (APs). Treatment choice is based on factors including patient
history and clinician preference. Because cost of patient care is often a factor, this
study explored the association between AP treatment choice and subsequent medical 
care costs. METHODS: Patients with BPD and AP treatment were identiﬁ ed in the
2004–2005 PharMetrics Patient-Centric Database. Patients were stratiﬁ ed by the 
most-recently prescribed AP and retained with q12 months continuous enrollment 
before and after their earliest AP claim. Total medical care costs were tallied from all
paid claims for 12 months post AP initiation. Multivariable analyses controlled for 
differences between cohorts. RESULTS: AP patient cohorts were ziprasidone (n  825), 
olanzapine (n  2526), risperidone (n  2309), quetiapine (n  2860) and aripiprazole
(n  1187). Mean age was 39–42 years. Ziprasidone patients were more likely to be 
female. Approximately 25% of the sample had comorbid anxiety and 10% had 
alcohol abuse. The majority had concomitant medication use. After controlling for 
covariates, the ziprasidone group’s 12-month post-initiation total costs ($14,445) were
similar to risperidone ($13,358, p  .06) and olanzapine ($13,780, p  0.24), and,
lower than quetiapine ($15,740, p  0.03) and aripiprazole ($16,360, p  0.01). Older 
age, female gender, pre-index psychiatric admission, comorbidities, and concomitant 
medication were signiﬁ cantly associated with increased costs. Nevertheless, unadjusted
results were similar to multivariable ﬁ ndings. CONCLUSIONS: Twelve months fol-
lowing treatment initiation for BPD, total medical care costs for patients on ziprasi-
done were comparable to those for patients on olanzapine or risperidone, and, 
signiﬁ cantly lower than costs for patients on quetiapine or aripiprazole. If cost is a
factor in AP treatment choice, the ﬁ ndings suggest ziprasidone compares favorably.
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OBJECTIVES: Efﬁ cacy in treating schizophrenia has been demonstrated for a variety 
of atypical antipsychotics (APs). Clinicians will select an appropriate AP based on a
variety of clinical considerations but cost of patient care is increasingly becoming a 
consideration. This study explored the association between AP treatment choice and 
subsequent medical care costs. METHODS: Patients with schizophrenia and AP treat-
ment were identiﬁ ed in the 2004–2005 PharMetrics Patient-Centric Database. Patients
were stratiﬁ ed by the most-recently prescribed AP and retained with q12 months 
continuous enrollment before and after their earliest AP claim. Total and psychiatric-
related medical care costs were tallied from all paid claims for 12 months post AP 
initiation. Multivariable analyses controlled for differences between cohorts.
RESULTS: Patient cohorts were ziprasidone (n  207), olanzapine (n  755), risperi-
done (n  1004), quetiapine (n  404) and aripiprazole (n  367). Mean age was 40–44 
years. Mood disorders, anxiety, alcohol abuse and substance abuse were prevalent 
among the sample. Most patients had concomitant medication use. After controlling 
for covariates, the ziprasidone group’s 12-month post-initiation total costs ($12,920) 
were similar to risperidone ($11,522, p  0.14), olanzapine ($13,398, p  0.65), que-
tiapine ($14,076, p  0.32) and aripiprazole ($13,286, p  0.75). Psychiatric-related
costs accounted for roughly half of total costs and were comparable across cohorts.
Comorbidities and concomitant medication were signiﬁ cantly associated with 
increased costs. Nevertheless, unadjusted results were similar to multivariable ﬁ ndings. 
CONCLUSIONS: In the 12 months following AP initiation total medical care and 
psychiatric-related costs for schizophrenia patients on ziprasidone were comparable 
to those for patients on other APs. If cost is a factor in AP treatment choice, the ﬁ nd-
ings suggest ziprasidone compares favorably.
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ECONOMIC IMPLICATION OF DOSE ESCALATION IN DEPRESSED
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OBJECTIVES: Dose escalation of antidepressant therapy is a common but potentially
costly strategy of managing treatment-refractory depression. This study assessed the
cost implications of dose escalation for major depressive disorder (MDD) patients
treated with escitalopram versus venlafaxine extended-release (XR). METHODS:
MDD patients (age q18) who started escitalopram or venlafaxine XR were identiﬁ ed
in the Ingenix Impact Database (2003–2006). The index date was the date when 
patients ﬁ rst received either drug at the label-recommended initial dose (escitalopram:
10 mg/day; venlafaxine XR: 75 mg/day) or high dose (escitalopram: 20 mg/day;
venlafaxine XR: 150 mg/day). Dose escalation was deﬁ ned as having a reﬁ ll with 
daily dose at least double the starting dose during the 6-month post-index period. A 
generalized linear model (GLM) assessed the effects of dose escalation and starting 
dose (recommended vs. high) on total health care costs during the post-index period, 
adjusting for index drug, demographics, comorbidities, and health care utilization at 
baseline. A similar GLM compared total costs between treatment groups, incorporat-
ing the effects of dose escalation and starting dose. RESULTS: 17,638 patients started
on escitalopram (18.6% on high-dose) and 9,252 on venlafaxine XR (46.0% on 
high-dose). Baseline mental comorbidities were similar between treatment groups. 
Venlafaxine XR patients had a 28.5% and 102.0% higher risk of dose escalation
compared to escitalopram patients in the recommended-dose and high-dose sub-
groups, respectively (both P  0.0001). Dose escalation and high starting dose were
associated with $1498 and $688 higher total costs, respectively (both P  0.0001). 
With lower starting dose and dose escalation risk, escitalopram patients incurred $198 
lower regression-adjusted total costs (P  0.0007) than venlafaxine XR patients. 
CONCLUSIONS: Dose escalation and high initial dose are associated with signiﬁ -
cantly higher total costs for adult MDD patients. Compared to venlafaxine XR 
patients, escitalopram patients are less likely to dose escalate or start on high-dose
treatment, and incur lower total costs.
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TREATMENT BURDEN AND COSTS OF LISDEXAMFETAMINE
DIMESYLATE USERS COMPARED WITH USERS OF OTHER LONG-
ACTING TREATMENTS IN PATIENTS WITH ATTENTION-DEFICIT
HYPERACTIVITY DISORDER
Christensen L1, Sasane R2, Hodgkins P2, Harley C3
1i3 Innovus, Ann Arbor, MI, USA, 2Shire Pharmaceuticals, Wayne, PA, USA, 3i3 Innovus, Eden
Prairie, MN, USA
OBJECTIVES: Lisdexamfetamine dimesylate (LDX), a therapeutically inactive mole-
cule, which after ingestion, is converted to l-lysine, and therapeutically active d-
amphetamine, is the ﬁ rst recently approved long-acting (LA) prodrug stimulant
indicated for the treatment of attention-deﬁ cit hyperactivity disorder (ADHD) in 
children and adults. This study examined adult patients in a US commercial health 
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plan database taking any of 5 long-acting ADHD medications to determine daily 
average consumption (DACON; pills per day) and ADHD pharmacy costs for LDX
compared with other therapies. METHODS: ADHD subjects aged 18–55 years with
at least one prescription for atomoxetine (n  513), methylphenidate (n  546), dex-
methylphenidate (n  124), mixed amphetamine salts (n  1,514), or LDX (n  246)
from July 1, 2007 through October 31, 2007 were studied retrospectively. Subjects
were continuously enrolled for 6 months before (baseline) and 6 months after (follow-
up) their ﬁ rst qualifying prescription. Subjects with an ICD-9 code for ADHD, but
with no ADHD prescriptions at baseline, were retained. Means were compared using
student’s t-test, proportions using chi-square, and ADHD medication costs in the 
follow-up period using Wilcoxon Mann Whitney test. RESULTS: The median number 
of LDX prescriptions (4) and days supplied (113) were highest (p  0.0001) compared
with all other medications in the follow-up period. Mean DACON was lowest for 
LDX (1.06; p  0.0001) and LDX had the highest proportion of patients (87.4%) 
with a DACON a 1. Higher DACON was associated with higher median cost for all
drugs (p  0.0001 for each), but incremental costs were lowest for LDX. CONCLU-
SIONS: Compared with four other drugs, LDX users had the lowest DACON, the 
highest proportion of patients with a DACON a 1, and longest therapy use in the
follow-up period, suggesting both real-world effectiveness and the possibility of better
patient compliance with LDX. Supported by funding from Shire Pharmaceutical 
Development Inc.
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OBJECTIVES: To inform providers and payers on the impact of depression in chronic 
medical disorders (CMD) in the United States (US), we studied national estimates of 
health service use and related costs in CMD patients with and without depression.
METHODS: For the retrospective analysis, we extracted data on /18 year-
old employed adults from the pooled 2004–5 Medical Expenditure Panel Survey. 
Data included ICD-9-CM-coded CMD (hyperlipidemia, heart disease, arthritis/other
joint-disorders, chronic obstructive pulmonary disease, hypertension, or diabetes),
depression, health service use (ambulatory, in-patient, and emergency department
visits and prescription medications) and related costs adjusted to 2005 US dollars. We
weighted sample estimates and 95% conﬁ dence limits (CL) using the Taylor expansion 
method. For CMD patients with and without depression, in univariate analyses using 
t-tests, we compared the mean number of ambulatory, in-patient, and emergency
department visits and prescription medications and related costs. RESULTS: On an 
average, CMD patients with depression (n  999) did signiﬁ cantly differ from those 
without depression (n  8739) by number of ambulatory visits (7.5, 95% CL: 6.9–8.1
vs. 4.6, 95% CL: 4.4–4.8, p  0.001) and related costs ($973, 95% CL: 867–1,094
vs. $567, 95% CL: 534–601 p  0.001) and by number of prescription drugs used 
(16.8, 95% CL:15.2–18.5 vs. 9.2, 95% CL:8.9–9.6, p  0.001) and related costs 
($1,012, 95% CL:918–1117 vs. $469, 95% CL: 442–497, p  0.001). However, CMD 
patients with depression did not signiﬁ cantly differ from those without depression for 
average number of inpatient hospital days or emergency department visits (p  0.05). 
CONCLUSIONS: Compared with CMD patients without depression, those with 
depression report 1.6- and 1.7-times higher ambulatory visits and related costs, and 
1.8- and 2.2-times higher mean number of prescription medications and related costs.
Factors associated with signiﬁ cant increases in health service use and related costs in
CMD patients with depression than those without depression need further study.
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OBJECTIVES: To examine hospitalization use and health care costs of elderly MDD
patients treated with escitalopram compared to those treated with either generic SSRIs 
or SNRIs. METHODS: Elderly MDD patients (age 65) initiated on escitalopram, a
generic SSRI, or SNRIs were identiﬁ ed in the Ingenix Impact Database (2003–2007). 
Hospitalization rates, length of stay, and health care costs were examined over the 
6-month period following therapy initiation (analysis period). Logistic and negative 
binomial regressions were used to compare the rate and days of hospitalization,
respectively. Wilcoxon tests were used to compare costs descriptively. General Linear
Model regression was conducted to control for patient characteristics including demo-
graphics, comorbidities, and baseline medical resource use. RESULTS: A total of 1850
elderly patients initiated on escitalopram, 2668 on generic SSRIs, and 1053 on SNRIs.
Escitalopram patients had higher comorbidities, health care utilization, and costs at 
baseline than generic SSRI and SNRI patients. Logistic regression showed that esci-
talopram patients were less likely to be hospitalized in the analysis period than generic 
SSRI (OR  0.81, P  0.0071) or SNRI patients (OR  0.88, P  0.1870). Negative
binomial regression showed that escitalopram patients had fewer hospitalization days
than generic SSRI (IRR  0.79, P  0.0416) and SNRI patients (IRR  0.74, P 
0.0442), which translated into 54.0 and 70.6 more days per 100 patients for the
generic SSRI and SNRI patients over 6 months, respectively. Escitalopram patients had
a $3,758 cost reduction during the analysis period, signiﬁ cantly greater than the cost
reductions for generic SSRI and SNRI patients of $951 and $562, respectively (both 
P  0.0001). GLM regression indicated that the 6-month risk-adjusted total health 
care costs for escitalopram patients were $985 (P  0.0758) and $1,889 (P  0.0080) 
lower than for generic SSRI and SNRI patients, respectively. CONCLUSIONS: Com-
pared to elderly MDD patients initiated on either generic SSRIs or SNRIs, patients
initiated on escitalopram had signiﬁ cantly fewer hospitalization days and lower health 
care costs.
PMH37
DISCRETE EVENT SIMULATION COMPARING QUALITY OF LIFE AND 
COSTS BETWEEN OLANZAPINE AND QUETIAPINE XR TREATMENT
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OBJECTIVES: To determine Quality of Life related to adverse reactions and costs 
using Olanzapine or Quetiapine XR in the treatment of Schizophrenia from an insti-
tutional perspective. METHODS: A Discrete Event model using Arena software was 
designed to calculate costs and Quality of Life (QoL) of Schizophrenia patients. Hos-
pitalization costs and time between relapses were obtained from an observational 
study performed in the Mexican Social Security Institute. This information was used 
to calculate random distributions for the model. Maintenance treatment costs were 
calculated using recommended doses and institutional drugs’ costs. Random distribu-
tions for adverse reactions were obtained from literature. QoL was assessed each year 
and costs were calculated for each patient applying a 3% discount rate. The model 
was run with ﬁ ve hundred patients for each cohort during a six-year period. A single 
variable sensitivity analysis was performed to evaluate the effect on compliance since 
the extended release formulation of Quetiapine is expected to improve compliance. 
Results are presented in US dollars with an exchange rate of 13.5 MXN pesos for 1 
US dollar. RESULTS: Annual average cost of treatment for Olanzapine cohort was 
$4,851 (95% CI, $4,632–$5,085) and for Quetiapine XR cohort $4,533 (95% CI, 
$4,334–$4,750) Average QoL for Olanzapine was 0.840 (95% CI, 0.839–0.842) and
for Quetiapine was 0.859 (95% CI, 0.857–0.861). The sensitivity analysis results 
showed a better QoL at a lesser cost in the worst assessed scenario with 60% compli-
ance in the Quetiapine XR cohort and 80% compliance in the Olanzapine cohort.
CONCLUSIONS: Quetiapine extended release is an atypical antipsychotic with less 
adverse reactions than Olanzapine that results in a better Quality of Life for patients 
with schizophrenia at a lesser cost for the institution.
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OBJECTIVES: To compare economic outcomes of MDD patients who were treated
with a patented SSRI (escitalopram, citalopram, sertraline, or paroxetine controlled-
release) and were switched to a generic SSRI for non-medical reasons vs. those continu-
ing on the patented SSRI. “Therapeutic substitution,” deﬁ ned as change from a 
branded product to a different generic compound in the same class, is a common 
practice encouraged by low co-pay for the generic products. METHODS: Adult MDD 
patients from the Ingenix Impact Database (2003–2007) were considered “switchers” 
if they were treated with a patented SSRI and switched to a generic SSRI. Those who
had an MDD-related urgent care (hospitalization or emergency room) or psychother-
apy visit in the seven days prior to switching were excluded. Patients who remained 
on the patented SSRI (“non-switchers”) were matched 1:1 to switchers. All-cause, 
mental health and MDD-related urgent care costs over six months were compared 
between switchers and non-switchers and regression models controlled for baseline 
differences. A subgroup analysis was conducted for patients treated with escitalopram. 
RESULTS: The study included 4449 matched pairs, 3304 (74%) of whom started on
escitalopram. Compared to non-switchers, switchers had higher risks of all-cause and 
mental health-related urgent care use (OR  1.15 and 1.34, respectively, P  0.01) and 
higher risk-adjusted MDD-related medical costs ($222, P  0.05). In escitalopram 
subgroup analyses, compared to non-switchers, switchers from escitalopram had even 
higher risks of all-cause (OR  1.21) and mental health-related urgent care use (OR 
 1.41, both P  0.01) and higher MDD-related medical costs ($151, P  0.05). 
CONCLUSIONS: Compared to patients who continued on escitalopram or patented
SSRIs, patients who switched to a generic SSRI incurred more urgent care resource
use and higher MDD-related health care costs. The effects of “therapeutic substitu-
tion” should be carefully examined because increasing utilization of drugs with lower 
acquisition costs may not be a cost-saving strategy, when total health care costs are 
considered.
